Alphyn Biologics is the leader developing a new class of drugs called Multi-target Therapeutics based on the therapeutic capabilities of its patent-pending AB-101 platform biomaterial. Alphyn’s AB-101 has over 40 bio-active compounds which provide Alphyn a rich and deep therapeutic product pipeline to treat and cure multiple diseases having no therapy or therapies with less than optimal results.
Alphyn includes all of AB-101’s bio-active compounds in each of its therapeutic products. The result is all Alphyn therapeutics have multiple compounds attacking the target disease providing multiple ways to treat and cure each disease. As multi-target therapeutics, Alphyn’s products are anticipated to be highly effective because AB-101 is expected to force the target disease to overcome multiple methods of attack. Alphyn’s therapeutics forcing the target disease to overcome multiple methods of attack should reduce the possibility of, or extend the time for, the disease to develop resistance to Alphyn’s products.
By including all of AB-101’s bio-active compounds in each Alphyn therapeutic product, Alphyn’s therapeutics can follow an accelerated timeline and reduced-cost path to FDA drug approval compared to standard drugs.
Alphyn is leading the way to more powerful and effective therapies. The use of all of AB-101’s bio-active compounds in Alphyn’s products establishes a new class of drugs – Multi-target Therapeutics.